ac1

NB001 (HTS 09836) is an adenyl cyclase 1 inhibitor that affects both neural and non-neural pain.

ST034307 is an effective and selective inhibitor of adenylyl cyclase 1 (IC50: 2.3 μM).

AC1-IN-1 is a selective inhibitor of adenylyl cyclase type 1 (AC1, IC50 = 0.54 µM).

Wnt pathway inhibitor 3 is a potent AC1 inhibitor (IC50: 45 nM) with antiproliferative activity, suitable for studies to ameliorate osteoarthritis in a mouse model of experimental osteoarthritis.

MAC13243 HCl, an inhibitor of LolA, a periplasmic chaperone that transports lipoproteins from the inner membrane to the outer membrane, is an antimicrobial agent with specificity and significant inhibitory effects on Gram-negative bacteria.

GLcNAc1-b-PNP is a chromogenic substrate for N-acetyl-β-glucosaminidase and can be used to quantify the activity of N-acetyl-β-D-glucosaminidase in human serum and urine.

NMac1 (Nm23 activator 1) is a natural compound, cassumunene, derived from Zingiber cassumunar Roxb. and traditionally used as an anti-inflammatory agent in East Asia. NMac1 exhibits anti-metastatic potential by directly interacting with the C-terminal of Nm23-H1, activating its NDP kinase (NDPK) enzymatic activity in vitro. NMac1 inhibits breast cancer metastasis in vivo.

(E)-NMac1 is a compound extracted from Java ginger, useful in cardiovascular disease and neurodegenerative disease research.

AC1115 is a highly effective and selective antiviral compound targeting SARS-CoV-2 Mpro and the host lysosomal cysteine protease cathepsin L (CTSL), exhibiting potent antiviral activity.

(2E)-N-(4-methoxyphenyl)-3-[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-enamide is a compound used as a molecular structural unit.

Rac1 Inhibitor W56 acetate(1095179-01-3 free base) is a peptide comprising residues 45-60 of the guanine nucleotide exchange factor (GEF) recognition/activation site of Rac1. Rac1 Inhibitor W56 acetate(1095179-01-3 free base) selectively inhibits Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1.

MBP Ac1-9, a peptide fragment of myelin basic protein (MBP), serves as an immunodominant epitope in experimental autoimmune encephalomyelitis (EAE) models, where it induces an immune response in T cells leading to pathological changes similar to multiple sclerosis. This peptide is used in research focused on T cell activation and autoimmune responses.

IDO1 and HDAC1 Inhibitor is a dual IDO1 and HDAC1 inhibitor (IC50s: 69.0 nM and 66.5 nM).

MAC13772 is a potent inhibitor of the enzyme BioA with an IC50 of 250 nM, thereby inhibiting biotin biosynthesis and exhibiting antibacterial activity.

HDAC1/6-IN-2 (I-c4), a dual inhibitor of HDAC1 and HDAC6, exhibits potent activity with IC50 values of 3.1 nM for HDAC1 and 2.95 nM for HDAC6. This compound demonstrates notable antitumor activity.

AC10142A, a selective inhibitor of Adenylyl Cyclase Type 1 (Adenylyl Cyclase Type 1), exhibits an IC50 of 0.26 μM. It is utilized in research models of pain.

TrimTAC1 is a PROTAC degrader that selectively targets the polyprotein Nucleoporin for degradation.

AC1115 TFA is a potent, selective antiviral drug and the active form of olgotrelvir. AC1115 TFA targets the Mpro of SARS-CoV-2 as well as the host lysosomal cysteine protease cathepsin L (CTSL), exhibiting high antiviral activity.

OAC1 (BAS 00287861) is a compound activating Octamer-binding transcription factor 4 (Oct4). It enhances the iPSC reprogramming efficiency and accelerates the reprogramming process.

HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.

HDAC11-IN-1 (Compound 14-NC6OH) is a macrocyclic inhibitor that selectively targets HDAC11 with a Ki of 40 nM. It demonstrates effective cell permeability and suppresses the expression of YAP1 and SOX2.

HDAC1-IN-9 (13c) is an HDAC1 inhibitor. It inhibits the HDAC1 enzyme with an IC50 value of 1.07 µM. This compound exhibits the strongest antiproliferative activity against HT-29 (human colon adenocarcinoma cells), with an IC50 of 1.78 μM. In HCT-116 (human colon cancer cells), HDAC1-IN-9 significantly induces apoptosis. Additionally, HDAC1-IN-9 possesses antiangiogenic properties, reducing the expression levels of VEGFR-2 and phosphorylated VEGFR-2 (pVEGFR-2) by approximately 80%.

HDAC11-IN-2 (compound B6) is a highly selective inhibitor of Histone Deacetylase 11 (HDAC11). It demonstrates IC50 values of 51.1 ×10^-3 μM for HDAC11 and 5 μM for HDAC8. HDAC11-IN-2 reduces de novo lipogenesis (DNL) and enhances fatty acid oxidation, which alleviates hepatic lipid accumulation and pathological symptoms in MASLD mice. By inhibiting HDAC11, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at the Thr172 site, thereby modulating de novo lipogenesis and fatty acid oxidation in the liver.

HDAC11-IN-3 (Compound A9) is a selective inhibitor of HDAC11, exhibiting an IC50 value of 4.1 nM. It demonstrates inhibitory effects on U937 and OCI-AML2 acute myeloid leukemia (AML) cell lines with an IC50 of 10 μM. This compound shows significant anti-AML activity by inducing apoptosis, cell cycle arrest, and differentiation. HDAC11-IN-3 upregulates the iron transport proteins transferrin (TF) and transferrin receptor (TFRC), and activates the p62-Keap1-Nrf2-HMOX1 pathway, which collectively increases intracellular iron levels and induces ferroptosis in AML cells. HDAC11-IN-3 can be utilized for AML research either alone or in combination with Cytarabine.